SENIORS is also the first major trial to test beta blockers in patients with preserved ejection fractions and showed similar benefits of nebivolol in this population as seen in patients with reduced ...

LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...

Finerenone's approval by the FDA to treat type 2 diabetes–associated chronic kidney disease was supported by data from the phase 2 FIDELIO-DKD trial; now, the results of FINEARTS-HF show real-world ...

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or ...